These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 3170105

  • 1. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones.
    Mitwalli A, Ayiomamitis A, Grass L, Oreopoulos DG.
    Int Urol Nephrol; 1988; 20(4):353-9. PubMed ID: 3170105
    [Abstract] [Full Text] [Related]

  • 2. [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
    Jaeger P, Portmann L, Jacquet AF, Burckhardt P.
    Schweiz Med Wochenschr; 1986 Dec 13; 116(50):1783-6. PubMed ID: 3798070
    [Abstract] [Full Text] [Related]

  • 3. Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors.
    Laminski NA, Meyers AM, Kruger M, Sonnekus MI, Margolius LP.
    Br J Urol; 1991 Nov 13; 68(5):454-8. PubMed ID: 1747716
    [Abstract] [Full Text] [Related]

  • 4. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria.
    Takei K, Ito H, Masai M, Kotake T.
    Urol Int; 1998 Nov 13; 61(3):192-5. PubMed ID: 9933846
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria.
    Edwards P, Nemat S, Rose GA.
    Urol Res; 1990 Nov 13; 18(6):393-6. PubMed ID: 2100414
    [Abstract] [Full Text] [Related]

  • 6. Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients.
    Ortiz-Alvarado O, Miyaoka R, Kriedberg C, Moeding A, Stessman M, Monga M.
    Urology; 2011 May 13; 77(5):1054-8. PubMed ID: 21334732
    [Abstract] [Full Text] [Related]

  • 7. Vitamin B6 metabolites in idiopathic calcium stone formers: no evidence for a link to hyperoxaluria.
    Kaelin A, Casez JP, Jaeger P.
    Urol Res; 2004 Feb 13; 32(1):61-8. PubMed ID: 14628106
    [Abstract] [Full Text] [Related]

  • 8. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F, CLU Working Group.
    Arch Ital Urol Androl; 2015 Jul 07; 87(2):105-20. PubMed ID: 26150027
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers.
    Nguyen QV, Kälin A, Drouve U, Casez JP, Jaeger P.
    Kidney Int; 2001 Jun 07; 59(6):2273-81. PubMed ID: 11380831
    [Abstract] [Full Text] [Related]

  • 10. Mild metabolic hyperoxaluria and its response to pyridoxine.
    Gill HS, Rose GA.
    Urol Int; 1986 Jun 07; 41(5):393-6. PubMed ID: 3811039
    [Abstract] [Full Text] [Related]

  • 11. Pyridoxine therapy in patients with renal calcium oxalate calculi.
    Balcke P, Schmidt P, Zazgornik J, Kopsa H, Minar E.
    Proc Eur Dial Transplant Assoc; 1983 Jun 07; 20():417-21. PubMed ID: 6657665
    [Abstract] [Full Text] [Related]

  • 12. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.
    Lindsjö M.
    Scand J Urol Nephrol Suppl; 1989 Jun 07; 119():1-53. PubMed ID: 2669121
    [Abstract] [Full Text] [Related]

  • 13. Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria.
    Yendt ER, Cohanim M.
    N Engl J Med; 1985 Apr 11; 312(15):953-7. PubMed ID: 3974685
    [Abstract] [Full Text] [Related]

  • 14. Modification of dietary oxalate and calcium reduces urinary oxalate in hyperoxaluric patients with kidney stones.
    Massey LK, Sutton RA.
    J Am Diet Assoc; 1993 Nov 11; 93(11):1305-7. PubMed ID: 8227883
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ALLN-177, oral enzyme therapy for hyperoxaluria.
    Lingeman JE, Pareek G, Easter L, Pease R, Grujic D, Brettman L, Langman CB.
    Int Urol Nephrol; 2019 Apr 11; 51(4):601-608. PubMed ID: 30783888
    [Abstract] [Full Text] [Related]

  • 17. Effect of pyridoxine supplementation on recurrent stone formers.
    Murthy MS, Farooqui S, Talwar HS, Thind SK, Nath R, Rajendran L, Bapna BC.
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep 11; 20(9):434-7. PubMed ID: 7141762
    [Abstract] [Full Text] [Related]

  • 18. Hyperoxaluria in idiopathic calcium nephrolithiasis--what are the limits?
    Osther PJ.
    Scand J Urol Nephrol; 1999 Dec 11; 33(6):368-71. PubMed ID: 10636575
    [Abstract] [Full Text] [Related]

  • 19. Dietary management of idiopathic hyperoxaluria and the influence of patient characteristics and compliance.
    Schwen ZR, Riley JM, Shilo Y, Averch TD.
    Urology; 2013 Dec 11; 82(6):1220-5. PubMed ID: 24054440
    [Abstract] [Full Text] [Related]

  • 20. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS, Hruska KA, Chandhoke PS.
    J Urol; 2003 Jun 11; 169(6):2030-3. PubMed ID: 12771711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.